Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Genie29jon Jan 29, 2023 5:15pm
87 Views
Post# 35253017

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:market CRAZYNESS

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:market CRAZYNESS

Nope - but I'm also not screaming "greed". 

What I am saying it's if people are claiming the Replicel team is "greedy" because they are buying at these low prices - it's a false claim bc WE ALL have  access to these special share offerings and/or the open market.

The way I see it is They (the Replicel team - aka Andrew) are doing everything they can keep this company afloat - I think every shareholder should be grateful for their investments vs criticizing. They clearly feel good about things, but need cash to at minimum get through the Shiseido hearing and getting the device to market. I cannot image they are pumping more cash into this company if they weren't optimistic. They may see the pot of gold at the end of this dark forest 

tgat said, I may invest on this round. I am already (very) heavily overweight in this company - so I am unsure I want to risk even more at this point, but tbd - I have bought more open market shares this past week. I would ideally like to see some positive news being released before I risk even more. 

<< Previous
Bullboard Posts
Next >>